| ¿µ¹® | test | ÇÑ±Û | °Ë»ç |
|---|---|---|---|
| ¼³¸í | ¾î¶² ´Ù¸¥ ¹°ÁúÀ» °ËÃâ, ÃøÁ¤, »ý¼ºÇϱâ À§ÇÑ Æ¯Á¤ÇÑ ÈÇйÝÀÀÀ» ÀÏÀ¸Å°´Âµ¥ »ç¿ëµÇ´Â ¹æ¹ý. |
||
| ¿µ¹® | scratch test | ÇÑ±Û | ³Àý¹ý |
|---|---|---|---|
| ¼³¸í | ÇǺθ¦ ³¯Ä«·Î¿î ¹Ù´Ã·Î ±Ü¾î ÇǺÎÀÇ ¹ÝÀÀÀ» º¸´Â °Ë»ç·Î ÇǺΠ°ú¹Î¹ÝÀÀÀ̳ª ¾Ë·¹¸£±â¸¦ ¾Ë¾Æº¸±â À§ÇÑ °Ë»çÀÌ´Ù. ¹Ù´Ã³¡¿¡ Ç׿øÀ» ¹¯Èù µÚ, ÇǺιØÀ» ±Ü¾î ¹ÝÀÀÀ» ¾Ë¾Æº»´Ù. À̶§ Ç׿øÀÌ ¾Æ´Ñ ´ëÁ¶¹°Áú(¿¹¸¦ µé¾î º¸ÅëÀÇ ¹°)À» ¹¯Èù ¹Ù´ÃÀ» °°ÀÌ ¹ÝÀÀÇÏ¿© ÇǺ馱âÁõ(dermographism) ´ÜÁö ¹Ù´ÃÀÇ ±ÜÈû¸¸À¸·Î ¾Ë·¹¸£±â °°Àº ¹ÝÀÀÀ» ÀÏÀ¸Å°´Â Çö»ó°ú °¨º°ÇØ¾ß ÇÑ´Ù. ³Ã», û·Â¼Ò½Ç(hearing loss) û°¢ÀÌ ÀúÇÏ ¶Ç´Â »ó½ÇµÈ »óÅÂ. ¿øÀΰú Á¤µµ´Â ¿©·¯ °¡ÁöÀε¥, ³Ã»Àº ±× Á¤µµ°¡ °¡Àå ½ÉÇÑ »óÅÂÀÌ´Ù. û°¢ÀÇ Àüµµ°æ·Î¿¡ Àå¾Ö°¡ ÀÖÀ» ¶§ ³Ã»ÀÌ ÀϾ°í, ±× º´ÅͰ¡ ¿ÜÀ̵µ³ª ÁßÀÌ¿¡ ÀÖ´Â °ÍÀ» ÀüÀ½³Ã», ³»ÀÌ¿¡ ÀÖ´Â °ÍÀ» °¨À½ ³Ã»À̶ó ÇÏ¿© ±¸ºÐÇÑ´Ù. ¶Ç º´ÅÍÀÇ ÀÚ¸®¸¦ ¸í½ÃÇÏ¿© ÁßÀ̼º ³Ã»À̳ª ¹Ì·Î¼º ³Ã» µîÀ¸·Î ¼¼ºÐÇϱ⵵ ÇÑ´Ù. |
||
| ¿µ¹® | stool guaiac test | ÇÑ±Û | ´ëº¯ ±¸¾ÆÀÌ¾Ç °Ë»ç |
|---|---|---|---|
| ¼³¸í | ´ëº¯³»¿¡ ÀÖÀ» ¼ö ÀÖ´Â ÀáÇ÷(´«¿¡ º¸ÀÌÁö ¾Ê´Â ÃâÇ÷)À¯¹«¸¦ °Ë»çÇÏ´Â ¹æ¹ýÀ¸·Î, Ç÷±¸³»ÀÇ heme peroxidase¿¡ ÀÇÇØ guaiacÀÌ »êȵǴ ¹ÝÀÀÀ» ÀÌ¿ëÇÏ¿© ÃøÁ¤ÇÑ´Ù. ¹æ¹ýÀº 3Àϰ£¿¡ °ÉÃÄ ÇÑ º¯¿¡¼ 2±ºµ¥¾¿ äÃëÇÏ¿© °Ë»çÇÑ´Ù. À§¾ç¼º ¹ÝÀÀ(°ÅÁþÀ¸·Î Ç÷¾×ÀÌ ÀÖ´Ù°í ³ªÅ¸³ª´Â ¹ÝÀÀ)Àº ½Ä¹° °ú»êÈÈ¿¼Ò¸¦ ÇÔÀ¯Çϰí ÀÖ´Â È«´ç¹«ÀÇ ¼·Ã볪 Ç÷±¸ ¼ººÐÀ» ÇÔÀ¯Çϰí ÀÖ´Â °í±â ¼·Ãë µî¿¡¼ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¸ç, À§À½¼º ¹ÝÀÀ(½ÇÁ¦·Î Ç÷¾×Àº ÀÖÁö¸¸, Ç÷¾×ÀÌ ¾ø´Ù°í ³ªÅ¸³ª´Â ¹ÝÀÀ)Àº ȯ¿ø·ÂÀ» °¡Áö°í ÀÖ´Â ºñŸ¹Î CÀÇ º¹¿ë½Ã ³ªÅ¸³¯ ¼ö ÀÖ´Ù. ƯÈ÷ À§¾ç¼º ¹ÝÀÀÀÌ ¸Å¿ì ÈçÇÏ´Ù. |
||
| ¿µ¹® | Rorschach Test | ÇÑ±Û | ·Î¸£»þÇÏ °Ë»ç |
|---|---|---|---|
| ¼³¸í | »ç°íÀå¾Ö¿Í Á¤¼Àå¾Ö¿¡ ¹Î°¨ÇÑ Åõ»ç°Ë»ç(projective test). °ËÀº»ö°ú ¸î°¡Áö »öÀ¸·Î ÀÌ·ç¾îÁø À×Å©¾ó·è°°Àº µµÇüÀÌ ±×·ÁÁø 10°³ÀÇ Ä«µå¸¦ ÀÌ¿ëÇÑ´Ù. ÇǰËÀÚ¿¡°Ô Ä«µå¸¦ º¸ÀÌ°í º» °Í¿¡ ´ëÇØ ¸»Çϵµ·Ï ÇÑ´Ù. ´ÙÀ½¿¡´Â ¾ó·èÀÇ ¾î´À À§Ä¡°¡ ÇǰËÀÚ°¡ ¸»ÇÑ Áö°¢´ë»óÀ» ¾Ï½ÃÇÏ´ÂÁö ãµµ·Ï ÇÑ´Ù. ÇǰËÀÚÀÇ ´äº¯À» ºÐ¼®ÇÏ¸é ±×ÀÇ »ç°í¿Í Á¤¼»óÅ¿¡ ´ëÇÑ Á¤º¸¸¦ ¾òÀ» ¼ö ÀÖ´Ù. |
||
| ¿µ¹® | Mantoux test | ÇÑ±Û | ¸ÁÅä¿ì°Ë»ç |
|---|---|---|---|
| ¼³¸í | ¼Ò¾Æ¿¡ ÁÖ·Î ½Ç½ÃÇÏ´Â °Ë»ç ¹æ¹ýÀ¸·Î, BCGÁ¢Á¾ÈÄ¿¡³ª ȤÀº °áÇÙ±Õ¿¡ ÇѹøÀÌ¶óµµ ³ëÃâµÈ °æ¿ì¿¡ ¾ç¼º¹ÝÀÀÀ¸·Î ³ª¿Â´Ù. ¿ì¸®³ª¶ó¿¡¼´Â »ýÈÄ 1°³¿ù¿¡ BCG¿¹¹æÁ¢Á¾À» ½ÃÇàÇϹǷΠ´ëºÎºÐ ¾ç¼ºÀ¸·Î ³ª¿À°Ô µÇ³ª, ÀÌ ¿¹¹æÁ¢Á¾À» ¹ÞÁö ¾ÊÀº »óÅ¿¡¼ ¾ç¼ºÀ¸·Î ³ª¿À¸é, °áÇÙ±ÕÀÇ Ä§Åõ¸¦ ÀǽÉÇÒ ¼ö ÀÖ´Ù. |
||
| ACD | absolute cardiac dullness; absolute claudication distance; acid-citrate-dextrose [solution]; actinom... |
|---|---|
| SSC | single-strand conformational [analysis]; sister strand crossover; somatosensory cortex; standard sal... |
| PAT | Pain Apperception Test; paroxysmal atrial tachycardia; patient; phenylaminotetrazole; physical abili... |
| CAT | California Achievement Test; capillary agglutination test; catalase; cataract; catecholamine; Childr... |
| TAT | tetanus antitoxin; thematic apperception test; thematic aptitude test; thrombin-antithrombin complex... |
| CGU | Cerebral glucose utilization |
|---|---|
| DUR | Drug Utilization Review |
| GUSTO-I | Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries |
| GU | Glucose utilization |
| NMCUES | National Medical Care Utilization and Expenditure Survey |
| carbohydrate utilization test | A test for the definitive identification of clinically important yeasts and yeastlike organisms. (05 Mar 2000) |
|---|---|
| drug utilization | The utilization of drugs as reported in individual hospital studies, FDA studies, marketing, or consumption, etc. This includes drug stockpiling, and patient drug profiles. (12 Dec 1998) |
| drug utilization review | Formal programs for assessing drug prescription against some standard. Drug utilization review may consider clinical appropriateness, cost effectiveness, and, in some cases, outcomes. Review is usually retrospective, but some analysis may be done before drugs are dispensed (as in computer systems which advise physicians when prescriptions are entered). Drug utilization review is mandated for medicaid programs beginning in 1993. (12 Dec 1998) |
| oxygen utilization coefficient | The extraction coefficient for oxygen in any given tissue. (05 Mar 2000) |
| utilization review | An organised procedure carried out through committees to review admissions, duration of stay, professional services furnished, and to evaluate the medical necessity of those services and promote their most efficient use. (12 Dec 1998) |
| utilization time | The minimum duration of a stimulus of rheobasic strength that is just sufficient to produce excitation. Synonym: temps utile. (05 Mar 2000) |
| acid-citrate-dextrose | A citrate anticoagulant used for the collection and preservation of whole blood. It has largely been replaced by newer coagulants (CPD, Adsol) that allow for longer shelf life for blood and blood products. Acronym: ACD (05 Mar 2000) |
| ATP citrate lyase | ATP citrate (pro-3S)-lyase |
| ATP citrate (pro-3S)-lyase | <enzyme> An enzyme that, in the presence of ATP and CoA, catalyses the cleavage of citrate to yield acetyl CoA, oxaloacetate, ADP, and orthophosphate. This reaction represents an important step in fatty acid biosynthesis. Chemical name: ATP:citrate oxaloacetate-lyase ((pro-S)-CH2COO(-)--acetyl-CoA) (ATP-dephosphorylating) Registry number: EC 4.1.3.8 Synonym: citrate cleavage enzyme. (12 Dec 1998) |
| bismuth ammonium citrate | Ammoniocitrate of bismuth; an intestinal astringent. (05 Mar 2000) |
| bismuth citrate | Used in the making of bismuth and ammonium citrate. (05 Mar 2000) |
| caffeine citrate | Citrated caffeine, a mixture of equal parts of caffeine and citric acid. (05 Mar 2000) |
| calcium citrate | <chemical> A colourless crystalline or white powdery organic, tricarboxylic acid occurring in plants, especially citrus fruits, and used as a flavoring agent, as an antioxidant in foods, and as a sequestrating agent. Pharmacological action: antioxidants. (12 Dec 1998) |
| carbetapentane citrate | 2-(Diethylaminoethoxy)ethyl 1-phenylcyclopentyl-1-carboxylate citrate;it has atropine-like and local anaesthetic actions and effectively suppresses acute cough due to common upper respiratory infections. (05 Mar 2000) |
| gallium-67 citrate | <radiology> Analogue of ferric iron, decay: by electron capture to ground state of Zn-67, energy levels: 92 KeV (40%); 184 KeV (23%); 296 KeV (21%), physiological half life: 3.3 days (78 hr), biological half life: 2-3 weeks, binding sites: serum: transferrin, haptoglobin, albumin, globulins, tissue: lactoferrin, PMN's (viable and nonviable), lymphocytes, macrophages, bacteria and fungi, tumour cell-associated transferrin receptor see: gallium: indications (12 Dec 1998) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|